RESEARCH

Neuromuscular junction pathology is correlated with differential motor unit vulnerability in spinal and bulbar muscular atrophy

Elana Molotsky¹, Yuhong Liu¹, Andrew P. Lieberman² and Diane E. Merry¹*

Abstract
Spinal and bulbar muscular atrophy (SBMA) is an X-linked, neuromuscular neurodegenerative disease for which there is no cure. The disease is characterized by a selective decrease in fast-muscle power (e.g., tongue pressure, grip strength) accompanied by a selective loss of fast-twitch muscle fibers. However, the relationship between neuromuscular junction (NMJ) pathology and fast-twitch motor unit vulnerability has yet to be explored. In this study, we used a cross-model comparison of two mouse models of SBMA to evaluate neuromuscular junction pathology, glycolytic-to-oxidative fiber-type switching, and cytoskeletal alterations in pre- and postsynaptic termini of tibialis anterior (TA), gastrocnemius, and soleus hindlimb muscles. We observed significantly increased NMJ and myofiber pathology in fast-twitch, glycolytic motor units of the TA and gastrocnemius compared to slow-twitch, oxidative motor units of the soleus, as seen by decreased pre- and post-synaptic membrane area, decreased pre- and post-synaptic membrane colocalization, increased acetylcholine receptor compactness, a decrease in endplate area and complexity, and deficits in neurofilament heavy chain. Our data also show evidence for metabolic dysregulation and myofiber atrophy that correlate with severity of NMJ pathology. We propose a model in which the dynamic communicative relationship between the motor neuron and muscle, along with the developmental subtype of the muscle, promotes motor unit subtype specific vulnerability, metabolic alterations, and NMJ pathology.

Keywords: SBMA, Neuromuscular junction, Skeletal muscle, Motor neuron

Background
Spinal and bulbar muscular atrophy (SBMA; Kennedy’s Disease) is an X-linked neuromuscular neurodegenerative disease caused by a polyglutamine-encoding CAG repeat expansion in exon 1 of the androgen receptor (Ar) gene [13, 30]. SBMA is characterized by limb and bulbar muscle weakness and atrophy and by the loss of lower motor neurons from the spinal cord and brainstem motor nuclei. Mutant AR-containing intranuclear inclusions are observed in remaining neurons, muscle, and to a lesser extent in tissues throughout the body that show little or no degenerative phenotype. The combination of lower motor neuron loss and muscle atrophy results in symptoms such as fasciculations, dysarthria, dysphagia, muscle weakness, and reduced muscle contractility [2]. Symptoms typically present between 30 and 50 years of age, and bulbar degeneration predisposes patients to potentially fatal aspiration pneumonia [17, 64]. Due to the requirement for testosterone for disease progression, SBMA is male-specific, although female patients are...
known to show mild or subclinical symptoms [65]. Currently there is no cure for this disease.

SBMA was historically classified as a lower motor neuron disease, and in SBMA patients, the loss of lower motor neurons results in a decrease in the number of functioning motor units compared to age-matched controls [67]. Mouse models recapitulate many aspects of motor neuron pathology such as intranuclear inclusions containing polyglutamine-expanded AR, electrophysiological alterations, neuronal loss, and decreased somal unphosphorylated neurofilament heavy chain [5, 9, 26, 71]. While earlier studies focused on the role of neurogenic degeneration of the motor unit in SBMA pathogenesis, many recent studies have elucidated a primary role for myogenic atrophy in SBMA. For example, when CAG-expanded Ar is selectively silenced in muscles of SBMA mouse models, disease phenotypes are substantially rescued, providing evidence for a primary myopathic disease mechanism [9, 34]. Moreover, metabolic and transcriptional dysregulation in muscle fibers could have non-cell autonomous effects on the health of the innervating motor neuron [47, 58], potentially contributing to motor neuron pathology in SBMA and degeneration of the motor unit.

Evidence of both myogenic and neurogenic disease processes places the neuromuscular junction (NMJ), the chemical synapse of the motor unit, at a focal point in SBMA pathogenesis. The unique synaptic structure of the NMJ ensures a high safety factor for neuromuscular transmission. Axon terminals of a pre-synaptic motor neuron must completely overlap with the pretzel-shaped acetylcholine receptor (AChR) clusters on the postsynaptic endplate to ensure that an action potential in the motor neuron reliably promotes contraction of the muscle fiber [31]. NMJs in multiple neuromuscular disease states including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and SBMA show a variety of structural pathologies such as fragmented AChR clusters, lack of AChR colocalization with the presynaptic terminal, denervation, loss of cytoskeletal elements, and a change in size or complexity (i.e., branching pattern) [36, 43, 51, 60]. Previous studies in SBMA mouse models revealed significant changes in NMJ structure and function [7, 27, 51, 60, 72]; however, the specificity of NMJ pathology to muscle and motor unit subtype has yet to be established.

Motor units, defined as the lower motor neuron and the muscle fibers it innervates, are classified as slow-twitch oxidative (Type I), fast-twitch oxidative (Type IIA), or fast-twitch glycolytic (Type IIB/x) based on the contractile properties of the muscular cytoskeleton. ‘Oxidative’ and ‘glycolytic’ refer to the metabolic machinery used to create ATP in the specified fiber type. Glycolytic (fast-twitch fibers) rely on glycolysis to provide energy, while oxidative (generally slow-twitch fibers) use both glycolysis and oxidative phosphorylation to create a sustained source of ATP for prolonged contraction. Importantly, the contractile properties of the muscle fiber are determined by the firing rate of its innervating motor neuron, which promotes a transcriptional program specific to muscle fiber types [66]. Preference loss of fast-twitch motor units has been seen in other neurodegenerative diseases such as ALS [11, 18, 19, 54], and glycolytic-to-oxidative fiber-type switching has been seen in mouse models of SBMA [7, 55, 58], as well as during normal aging [25]. In SBMA patients, decreased tongue pressure and grip strength, along with fast-twitch muscle fiber atrophy, suggest selective fast motor unit degeneration [17, 23, 73]; however, the vulnerability of fast-twitch motor units, and the relationship between NMJ structural pathology and the differential vulnerability of fast- and slow-twitch motor units in SBMA has yet to be evaluated.

In this study, we aimed to evaluate the NMJ pathology in relation to fiber type vulnerability to further understand the intersection of neuronal and myofibrillar pathology in multiple muscles of SBMA mouse models. We determined the relationship between NMJ structural pathology and motor unit subtype (fast- vs. slow-twitch) using two mouse models of SBMA—a transgenic, CNS expression-focused mouse model of SBMA [5] and a knock-in mouse model of SBMA [74, 75]. We evaluated multiple aspects of NMJ morphology in three muscles of distinct fiber type—gastrocnemius and tibialis anterior (TA), both largely fast-twitch, glycolytic muscles, and soleus, a largely slow-twitch, oxidative muscle. We hypothesized that NMJ structural pathology in these mouse models would correlate with the increased vulnerability of fast-twitch motor units seen in both SBMA mouse models and patients, showing, for example, increased endplate fragmentation and decreased pre- and post-synaptic colocalization.

We observed significant NMJ structural pathology in all three muscles of both mouse models, with more severe NMJ pathology in muscles composed primarily of fast-twitch myofibers. Cytoskeletal alterations in both motor neurons and muscle, namely decreased NFH and altered myosin heavy chain expression, provide evidence for both neuropathic and myopathic contributions to NMJ pathology in these SBMA models. Analysis of muscle histology to further understand myofiber changes in relation to NMJ pathology revealed a prominent shift to oxidative metabolism and a decrease in cross sectional area in all muscles of both mouse models, with fast-twitch muscles showing more severe muscle pathology. These quantitative studies
provide significant evidence of correlated neuronal and muscular dysregulation that contribute to NMJ pathology, which is more severe in fast-twitch motor units. We propose a model in which both the contractile properties of the motor unit and the developmental subtype of the muscle contribute to disease pathology at the NMJ of SBMA model mice and highlight the importance of robust and quantitative NMJ evaluations for the understanding these contributions.

Methods

Mouse models

Animal care and experimental procedures were conducted in accordance with the Thomas Jefferson University Institutional Animal Care and Use Committee (IACUC). Transgenic Model: The transgenic model, previously described in Chevalier-Larsen et al., 2004 [5], uses the prion protein promoter to express an expanded human AR containing 112 CAG repeats (+1 CAA codon, encoding a total of 113 glutamine residues within the human AR protein) primarily in the central nervous system. Knock-in Model: The knock-in model, previously described in Yu et al., [74, 75], replaces part of the exon 1 of the mouse androgen receptor gene with a portion of human Ar exon 1 containing 112 CAG repeats (+1 CAA codon, encoding a total of 113 glutamine residues within the human AR protein) resulting in endogenous expression levels and pattern of polyglutamine expanded androgen receptor.

Neuromuscular junction analysis

Muscles of 3 mice of each genotype (1-year-old non-transgenic and transgenic mice, and 6-month-old wildtype and knock-in mice) were dissected. Gastrocnemius, tibialis anterior, and soleus muscles were dissected from SBMA mice and littermate controls and immediately placed into 4% paraformaldehyde (PFA) for 30 min. Muscles were then teased into small bundles under a dissecting microscope in PBS and stained according to Martin et al., 2015 [41]. Briefly, teased muscle was incubated in 0.1 M glycine solution, incubated in AlexaFluor-647-conjugated α-bungarotoxin, then incubated in pre-cooled methanol. Muscles were incubated in blocking buffer (2% bovine serum albumin in 0.2% Triton-X-100) and then incubated with primary and then secondary antibodies in blocking buffer. Muscles were mounted on microscope slides using Fluoromount-G mounting medium and imaged on a Nikon A1R confocal microscope. At least 20 neuromuscular junctions from each muscle were imaged. Antibodies used are provided in supplementary methods.

Image analysis of neuromuscular junctions

At least 20 neuromuscular junctions from each muscle were evaluated with the following protocol using ImageJ, adapted from Jones et al. [24]. Full analysis protocol is provided in supplementary methods (schematic shown in Additional File 1: Fig. S1).

Immunohistochemical analysis of muscle

NADH-TR (diaphorase): Muscle sections were incubated in NADH-tetrazolium solution (NADH, Sigma N8129; Nitro blue tetrazolium, Sigma N6876) for 30 min at 37 °C. Unbound solution was removed from muscle sections using by successive washes with 30% acetone, 60% acetone, 90% acetone, 60% acetone, and 30% acetone. Sections were mounted with CitriSolve. Images were taken at 10X using an EVOS M7000 microscope. Intensity of NADH staining and cross-sectional area were analyzed in ImageJ by manually selecting each muscle fiber and recording mean intensity and area. 3 images were analyzed (≥ 574 fibers) per muscle for each genotype.

Androgen Receptor: Muscle sections of gastrocnemius from one knock-in mouse and one transgenic mouse were fixed in 4% PFA for 20 min, and stained as in Montie et al. [46]. Images were taken at consistent exposure on an EVOS M7000 microscope at 60x. 15 images per muscle were evaluated in ImageJ by selecting a region of interest for each muscle fiber and measuring mean intensity of AR fluorescence. All images were taken at the same exposure.

Western blot analysis

Gastrocnemius, tibialis anterior, and soleus muscles were dissected from 3 mice of each genotype and flash-frozen in liquid nitrogen (12-month-old non-transgenic and transgenic, 9 month old knock-in mice). Muscles were manually pulverized with a mortar and pestle and added to lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton-X-100, 1% sodium deoxycholate, 0.1% SDS, 2 mM EDTA, 1X Roche Protease Inhibitors, PMSF). Lysate was then homogenized using a Cole-Parmer LABGEN 850 Homogenizer; 110 V at 13,000 rpm 3 x 20 s. Lysate was then sonicated and centrifuged at 4 °C at 15,000 g for 10 min. Protein concentration was measured using the BioRad DC Assay Kit. 50ug of protein extract was electrophoresed on TGX Stain-Free FastCast™ polyacrylamide gel (BioRad). Membrane was blocked in 0.05% TBST with 5% milk. Primary and secondary antibody details are provided in supplementary methods.
**Results**

To investigate the structural pathology of the NMJ in slow- and fast-twitch motor units, soleus, gastrocnemius, and TA muscles were dissected from two mouse models of SBMA and evaluated for multiple features of NMJ pathology. The first mouse model, hereafter referred to as the **knock-in model** [74, 75], exhibits a progressive decrease in strength as early as 12 weeks of age, both neurogenic and myopathic muscle atrophy (with myopathic features preceding neurogenic atrophy), and fiber-type grouping [16, 58, 74, 75]. These mice also show partial fragmentation at the NMJ without denervation at 6 months of age [51]. The second mouse model used in this study, hereafter referred to as the **transgenic model**, exhibits slowly progressive motor deficits as early as 8 weeks of age and shows mutant androgen receptor (AR) intranuclear inclusions in spinal cord and skeletal muscle. It also exhibits muscle atrophy and shows no motor neuron loss in vivo, although extensive motor neuron death is observed in vitro upon hormone treatment [20, 45, 48, 50].

To understand the relationship between NMJ and muscle pathology, we aimed to evaluate both transgenic and knock-in mice at 6-months of age due to the presence of significant motor dysfunction and muscle atrophy in both models [5, 74, 75]. At 6-months of age, the knock-in mice show no motor neuron loss [34], and the transgenic mice show no motor neuron loss throughout their lifespan [5]. This cross-model comparison aimed to evaluate NMJ pathology at timepoints known to be devoid of motor neuron loss. However, due to the lack of NMJ pathology in the transgenic mice at 6-months of age (Additional File 1: Fig. S1), we evaluated the transgenic model at 1 year of age and the knock-in model at 6-months of age in order to better understand the extent of NMJ pathology in the absence of motor neuron loss.

**Gastrocnemius muscle shows significant neuromuscular junction pathology in two mouse models of SBMA.**

To understand how mutant AR expression affects the NMJ, the primarily fast-twitch gastrocnemius muscles from both mouse models were evaluated for NMJ pathology (Additional File 1: Fig. S1). Post-synaptic area was found to be substantially decreased in both transgenic and knock-in mice compared to control littermates (Fig. 1A–C). Endplate area was also substantially decreased in both models (Fig. 1D, E). AChR compactness, calculated by dividing post-synaptic area by endplate area, was increased in both models but only reached statistical significance in the knock-in model (Fig. 1F, G). Both models showed a decrease in endplate complexity, but this only reached statistical significance in knock-in NMJs (Fig. 1H, I). Both models showed a modest increase in the percentage of fragmented NMJs; however, this did not reach statistical significance (Fig. 1J, K), highlighting the value of exploring quantitative measurements of NMJ pathology. Presynaptic area, measured using localization of synaptic vesicle protein synaptophysin, was significantly reduced in both models (Fig. 2A–C). Pre- and post-synaptic colocalization was also decreased in both models (Fig. 2D–F). These detailed quantitative data (Additional File 1: Table S1) provide evidence for significant pre- and post-synaptic pathology at the NMJs of the primarily fast-twitch gastrocnemius muscle in two mouse models of SBMA.

Previous studies in a transgenic model of SBMA revealed a significant reduction in unphosphorylated neurofilament heavy chain (uNFH) in the cell bodies of spinal motor neurons [5]. At the axon terminal of NMJs in the gastrocnemius, uNFH intensity was significantly decreased in both models (Additional File 1: Table S1). Moreover, localization of uNFH to the axon terminal, as measured by colocalization with fluorescently tagged α-BTX, was decreased in gastrocnemius of the knock-in model (Fig. 3C, D), and trended lower in the transgenic model (Fig. 3A, B). Since NFH is increasingly phosphorylated as it travels in the anterograde direction towards the axon terminal, we also evaluated phosphorylated NFH (pNFH) localization to the axon terminal through colocalization with synaptophysin (Fig. 3E, G). In both mouse models, although pNFH intensity was unchanged (Additional File 1: Fig. S3),
Fig. 1 (See legend on previous page.)
pNFH colocalization with the pre-synaptic terminal was decreased (Fig. 3F). These data provide evidence for a significant deficit in NFH at the axon terminal, which correlates with the substantial pre- and post-synaptic alterations in NMJs of the gastrocnemius.

Fast-twitch tibialis anterior motor units show significant changes in the post-synaptic membrane of the NMJ.

To further evaluate the pathology of fast-twitch motor units in these two mouse models of SBMA, we evaluated NMJs in fast-twitch TA using the same procedure (See figure on next page.)

**Fig. 2** Gastrocnemius NMJs show significant decreases in pre-synaptic area and pre- and post-synaptic colocalization in transgenic and knock-in models of SBMA. Pre-synaptic terminals were stained with synaptic vesicle marker synaptophysin and measured for pre-synaptic area and colocalization with post-synaptic membrane, labeled with fluorescently tagged α-bungarotoxin. Arrows point to NMJ with low synaptophysin staining. Synaptophysin image in A were merged with α-BTX images for panel D. A Gastrocnemius NMJs showed significantly decreased pre-synaptic area in transgenic and knock-in mice (B NTg vs Tg p < 0.0001; C WT vs KI p < 0.0001). D Gastrocnemius NMJs showed significantly decreased pre- and post-synaptic colocalization in transgenic and knock-in mice (E NTg vs Tg, p < 0.001; F WT vs KI, p < 0.01). Mann–Whitney Test was used to evaluate statistical significance for distributions. Abbreviations: NTg, non-transgenic; Tg, transgenic; WT, wild-type; KI, knock-in

**Fig. 3** Gastrocnemius NMJs show significant changes in localization of phosphorylated and unphosphorylated neurofilament heavy chain to the axon terminal in two mouse models of SBMA. (A, C, E, G) To evaluate localization of cytoskeletal structural element NFH to the axon terminal, NMJs from gastrocnemius were stained with α-BTX, synaptophysin, and SMI31 (phospho-NFH) or α-BTX, TUJ1 (BIII-tubulin), and SMI32 (unphospho-NFH) and evaluated for colocalization with synaptophysin or α-BTX, respectively. B, D Both transgenic (trending, p = 0.0618) and knock-in mice (p < 0.0001) showed decreased uNFH localization to the terminal. E, H Both transgenic (p < 0.001) and knock-in (p < 0.01) mice also showed significantly decreased pNFH colocalization with the terminal. Mann–Whitney Test was used to evaluate statistical significance: uNFH Unphosphorylated neurofilament heavy chain; pNFH Phosphorylated neurofilament heavy chain; NTg Non-transgenic; Tg Transgenic; WT Wild-type; KI Knock-in
Fig. 3 (See legend on previous page.)
described for the analysis of gastrocnemius. In the transgenic mouse model, TA NMJs showed a significant decrease in post-synaptic area and endplate area, without a corresponding increase in acetylcholine receptor compactness (Fig. 4A, B, D, F). However, unlike gastrocnemius NMJs, TA NMJs in the transgenic model showed a significant increase in fragmentation, a well-studied indicator of NMJs that are degenerating or remodeling [63]. In comparison, NMJs of knock-in TA showed a significant change only in AChR compactness (Fig. 4G), despite showing no significant differences in post-synaptic area or endplate area (Fig. 4C, E). Knock-in TA NMJs showed no change in fragmentation (Fig. 4I). There were no significant changes in endplate complexity or in
any pre-synaptic markers, including area and pre- and postsynaptic colocalization, in the TA of either model (Additional File 1: Fig. S4). These data (Additional File 1: Table S1) provide evidence for more limited NMJ pathology in the NMJs of TA, observed primarily in the postsynaptic membrane, in contrast to the more substantial pre- and post-synaptic pathology seen in the gastrocnemius muscle, despite the fact that both muscles contain primarily fast-twitch muscle fibers.

Although pathology at the NMJ of TA muscles in transgenic mice was observed primarily at the post-synaptic membrane (post-synaptic area, endplate area, and fragmentation), alterations in pNFH intensity (Additional File 1: Fig. S5) and localization to the axon terminal (Fig. 5E, F) were present at the pre-synaptic membrane of NMJs of the TA in transgenic mice. In addition, uNFH localization to the pre-synaptic terminal was also significantly decreased in this model (Fig. 5A, B), providing evidence for general NFH depletion at the NMJ. In contrast, the NMJs of TA in knock-in mice showed a significant increase in pNFH staining intensity compared to littermate controls (Additional File 1: Fig. S5) and did not show changes in uNFH intensity or localization of pNFH or uNFH to the pre-synaptic terminal (Fig. 5C, D, G, H). The changes in NFH at TA NMJs appear to correlate with the severity of NMJ pathology observed in both models – the transgenic model, which showed multiple signs of NMJ structural deficits, also showed substantial decreases in NFH, while the knock-in model, which only showed alterations in AChR compactness, showed increased pNFH intensity and no changes in colocalization of NFH with the pre-synaptic terminal.

**Slow-twitch soleus shows less NMJ pathology than fast-twitch muscles**

To evaluate differences between fast-twitch and slow-twitch motor unit pathology, we evaluated NMJs of the slow-twitch soleus muscle in both mouse models of SBMA. In transgenic mice, soleus NMJs exhibited modestly decreased endplate area, pre- and postsynaptic colocalization, and endplate complexity (Fig. 6), with a trend toward an increase in AChR compactness. There were no significant changes in postsynaptic area, presynaptic area, or fragmentation (Additional File 1: Fig S6). Transgenic mice also showed a significant decrease in pNFH colocalization with the pre-synaptic terminal, without alterations in pNFH intensity, uNFH intensity, or uNFH localization to the terminal (Fig. 7A, B, E, F; Additional File 1: Fig. S7). Moreover, soleus NMJs from knock-in mice exhibited no significant changes in any of the evaluated parameters (Additional File 1: Fig. S6), except a decrease in uNFH intensity and uNFH localization to the pre-synaptic terminal (Fig. 7C, D, G, H; Additional File 1: Fig. S7).

These data support the hypothesis that slow-twitch motor units exhibit substantially less NMJ pathology than fast-twitch motor units, as both models exhibited stark differences in NMJ pathology between fast- and slow-twitch motor units (Additional File 1: Table S1).

**AR expression is not significantly different in muscles of transgenic and knock-in mice.**

To further understand possible mechanisms driving the heightened NMJ pathology in transgenic mice compared to knock-in mice in both TA and soleus muscles, we considered the differences in AR expression between the two models. AR expression is substantially greater in the spinal cord of transgenic mice compared to non-transgenic mice [5, 77]. Because knock-in mice express polyglutamine-expanded AR under mouse regulatory gene elements, AR expression in these mice is equal to that in non-transgenic mice which endogenously express non-expanded AR. Additionally, while the transgenic mice primarily express polyglutamine-expanded AR in the central nervous system, polyglutamine-containing intranuclear inclusions are seen in muscle (Additional File 1: Fig. S8). We evaluated AR protein expression in gastrocnemius muscle fibers from transgenic and knock-in mice (Additional File 1: Fig. S8) and observed no significant differences between the two models in AR intensity. Therefore, the differences in NMJ pathology between transgenic and knock-in mice are unlikely to be attributed to elevated AR expression in transgenic muscle. Our results thus suggest that the increased levels of polyglutamine-expanded AR in the
Fig. 5 (See legend on previous page.)
spinal cord of the transgenic mice likely contribute to the greater NMJ pathology in transgenic soleus and TA muscles.

**Acetylcholine receptor subunit expression is altered in SBMA muscle**

Previous studies revealed increased AChR gamma mRNA in transgenic and knock-in mouse models of SBMA, corresponding to electrophysiological changes in NMJ transduction in extensor digitorum longus and levator ani muscles [71]; therefore, we explored whether AChR gamma protein levels correlated with NMJ pathology. Nicotinic AChRs are composed of five subunits -- two alpha, one beta, one delta, and either one gamma or epsilon subunit, depending on the developmental stage of the organism, with the epsilon subunit expressed at mature NMJs and the gamma subunit expressed in fetal or denervated NMJs [44, 69]. Gamma subunits are also expressed at the NMJs of intrafusal muscle fibers [15]. We evaluated AChR gamma protein expression by Western blot and observed a trend toward decreased expression in the soleus of both transgenic and knock-in mice (Additional File 1: Fig. S9A). In contrast to these observations in the soleus, the TA exhibited increased AChR gamma levels in knock-in mice, which similarly trended higher in transgenic mice (Additional File 1: Fig. S9B).

**(See figure on next page.)**

**Fig. 6** Slow-twitch soleus shows moderate NMJ pathology in transgenic, but not in knock-in, model of SBMA. Pre-synaptic membranes of NMJs from soleus muscle were stained with synaptic vesicle marker synaptophysin and post-synaptic membranes were labeled with fluorescently tagged α-bungarotoxin (α-BTX). A. Transgenic mice showed a significant decrease in endplate area (B; *p* < 0.05), pre- and post-synaptic colocalization (D; *p* < 0.05), and post-synaptic complexity (E; *p* < 0.001). AChR compactness trended to an increase in transgenic mice, but this did not reach statistical significance (C). Knock-in mouse NMJs of the soleus did not show any significant changes in NMJ pathology compared to WT littermates (Additional File 1: Fig. S6). Mann–Whitney Test was used to evaluate statistical significance. NTg Non-transgenic; Tg Transgenic; WT Wild-type; KI Knock-in

**Fig. 7** Soleus NMJs show significant decrease in localization of NFH to the axon terminal. A, C, E, G To evaluate localization of cytoskeletal structural element NFH to the axon terminal, NMJs from tibialis anterior were stained with α-BTX, synaptophysin, and SMI31 (phospho-NFH) or α-BTX, TUJ1 (BIII-tubulin, and SMI32 (unphospho-NFH) and evaluated for colocalization with the synaptophysin or α-BTX, respectively. B Transgenic mice showed no changes in uNFH localization to the terminal; however, knock-in mice showed a significant decrease in uNFH localization with the terminal (D; *p* < 0.05). D In contrast, pNFH colocalization with the terminal was significantly decreased in transgenic mice (E; *p* < 0.01) but not in knock-in mice (F). Mann–Whitney Test was used to evaluate statistical significance. uNFH Unphosphorylated neurofilament heavy chain; pNFH Phosphorylated neurofilament heavy chain; NTg Non-transgenic; Tg Transgenic; WT Wild-type; KI Knock-in
Fig. 7 (See legend on previous page.)
Muscle fibers in gastrocnemius, tibialis anterior, and soleus muscles exhibit a shift to increased oxidative metabolism and decreased cross-sectional area

Because the NMJ is the chemical synapse between the motor neuron and the muscle fibers it innervates, it is important to consider muscle fiber changes that occur concomitant with NMJ pathology. Using nicotinamide adenine dinucleotide (NADH)-diaphorase staining, we evaluated cross-sections of gastrocnemius for evidence of muscle atrophy and fiber-type switching (Fig. 8A). As expected, due to the high proportion of fast-twitch glycolytic fibers in gastrocnemius muscles, non-transgenic/wild-type gastrocnemius muscle fibers showed light staining with little pigment deposition. Both transgenic (Fig. 8A, B) and knock-in (Fig. 8A, C) gastrocnemius muscle fibers showed substantially increased staining intensity, suggesting a shift to more oxidative metabolism. Moreover, the cross-sectional area of gastrocnemius muscle fibers was significantly decreased in both models (Fig. 8K, M), as seen in gastrocnemius and TA muscles in both models. However, unlike knock-in mice, transgenic mice showed a significant decrease in NADH staining (Fig. 8K, L). This unexpected result could result from an oxidative-to-glycolytic shift as a result of altered metabolism [49] or from reduced oxidative capacity due to disease progression. It is worth noting that, while soleus muscles of both the knock-in and transgenic mouse models showed significant decreases in cross-sectional area, a much more substantial decrease was observed in transgenic mice (Fig. 8K, N) compared to knock-in mice (Fig. 8K, O; Additional File 1: Table S2).

The combined histological and structural analyses of muscle fibers in the two mouse SBMA mouse models used here indicate that muscles composed of primarily fast-twitch fibers exhibit a substantial shift from glycolytic to oxidative metabolism, with a corresponding decrease in cross-sectional area. Slow-twitch soleus muscles, in contrast, exhibited an oxidative shift that was observed only in the knock-in model. Irrespective of the oxidative state of the individual muscle fibers, all muscle fibers exhibited substantially decreased cross-sectional area, which was more severe in the transgenic mice. The greater muscle pathology observed in the transgenic model correlates with the increased NMJ pathology in

Fig. 8). Gastrocnemius, however, did not show any alterations in AChR gamma protein levels, despite exhibiting even greater NMJ pathology than TA (Additional File 1: Fig. S9C). Thus, in the absence of a correlation between AChR gamma expression and NMJ pathology, it is unlikely that heightened AChR gamma expression plays a role in or serves as a marker of motor unit vulnerability in these models.
Fig. 8 (See legend on previous page.)
Muscle cytoskeletal protein expression is significantly altered in transgenic and knock-in mice

Vinculin, a cytoskeletal component of striated muscle, is present in significantly greater quantities in slow-twitch, oxidative, muscle fibers than in fast-twitch, glycolytic, muscle fibers, and meta-vinculin, a vinculin splice isoform, is present only in fast-twitch muscle fibers of wild-type mice (Fig. 9) [8]. Denervation of TA in multiple mouse models resulted in increased vinculin levels [57], leading us to question whether vinculin levels in the three muscles evaluated here were altered. Western
blot analysis of gastrocnemius, TA, and soleus revealed increased vinculin levels in all three muscles of knock-in mice and in TA of transgenic mice (Fig. 9A, E, I), with a trending increase in gastrocnemius and soleus of the transgenic mice. This increase in vinculin expression is consistent with a shift in these muscles to a more oxidative metabolism, as vinculin is highly expressed in slow-twitch muscle fibers to enable sustained contraction [8].

To further understand a possible fast-to-slow fiber-type switch and the glycolytic-to-oxidative metabolic shift, we evaluated myosin heavy chain (MHC) isoform expression in soleus, TA, and gastrocnemius of both mouse models. Contrary to our hypothesis that gastrocnemius and TA muscles would exhibit a switch to increased expression of an oxidative, slow-type muscle MHC (MHC type I), gastrocnemius and TA showed a significant decrease in MHC I expression in both transgenic and knock-in muscle (Fig. 9B, F). As expected, both of these primarily fast-twitch muscles showed significantly decreased fast-twitch MHC isoform, MHC IIB, although in gastrocnemius this only reached significance in the knock-in mice (Fig. 9D, H). MHC IIA, primarily found in oxidative fast-twitch fibers, was not significantly changed in gastrocnemius (Fig. 9C) and was undetectable in TA. Together, these data point to a decrease in overall MHC protein expression rather than a switch in contractile fiber-type. Soleus muscles in both transgenic and knock-in mice showed a significant increase in MHC I and MHC IIA expression compared to non-transgenic controls (Fig. 9, K). As expected, the soleus of all three genotypes did not express fast-twitch myosin heavy chain, MHC IIB.

Discussion

Spinal and bulbar muscular atrophy (SBMA) is a debilitating neuromuscular neurodegenerative disease for which there is no cure [13]. Symptoms reflect neuromuscular system degeneration and implicate dysfunctional communication at the primary functional synapse of the motor unit, the neuromuscular junction (NMJ). It has been shown previously in both SBMA and ALS that fast-twitch motor units are more susceptible to degeneration than slow-twitch motor units [19, 42, 73]. However, it is unknown whether pathology at the NMJ differs between motor unit subtypes in SBMA. Based on previous data showing a loss of fast-twitch muscle fibers in SBMA patients and SBMA mouse models [7, 23, 58, 73], we hypothesized that TA would show significant NMJ pathology due to its classification as a fast-twitch muscle, and that fast-twitch gastrocnemius would show equal or less pathology than TA due to the higher percentage of type I (slow) and IIa (fast-oxidative) fibers [3]. Correspondingly, we hypothesized that slow-twitch soleus muscle would show little to no evidence of NMJ pathology.

In this study, our data revealed, as expected, that fast-twitch motor units of the gastrocnemius and TA showed more severe NMJ pathology than slow-twitch motor units of the soleus, and that this difference correlated with metabolic and structural changes in the innervated muscle fibers. However, our observations suggest a more complex interpretation than originally hypothesized, as NMJ pathology in the TA was limited to post-synaptic changes only in the transgenic model and was less severe than NMJ pathology in the gastrocnemius, even though both are considered fast-twitch muscles. One possible explanation for these observations is the developmental difference between gastrocnemius and TA in AChR clustering. It is known that, in response to disease and/or injury, both myofibers and motor neurons reinitiate the developmental program [21, 22, 78]. During development, TA myofibers exhibit fast-synapsing (FaSyn) characteristics, while gastrocnemius and soleus exhibit delayed-synapsing (DeSyn) features [53]. FaSyn TA myofibers focally cluster AChRs and align motor nerves with AChR clusters at a substantially faster rate during development than DeSyn gastrocnemius and soleus myofibers, and differences in AChR clustering occur even in the absence of an innervating motor neuron [53]. This developmental difference impacted disease severity in a model of MuSK-induced myasthenia gravis, in which NMJs of DeSyn muscles showed significantly decreased post-synaptic area compared to NMJs of FaSyn muscles [70]. The ability of TA (FaSyn) to focally cluster AChRs at a higher rate could have an impact on its ability to respond to disease pathology when the developmental program is re-initiated, resulting in less NMJ pathology than its fast-twitch counterpart, gastrocnemius (DeSyn). Of note, TA was the only muscle evaluated that showed upregulated AChR gamma (Additional File 1: Fig. S9), which is known to be required for AChR clustering during development [37]. We hypothesize that the upregulated expression of AChR gamma in diseased TA is related to its classification as a FaSyn muscle. Validation of this idea that intersecting developmental and degenerative mechanisms contribute to NMJ pathology in SBMA requires further validation.

NMJs in all three muscles evaluated in this study showed significant changes in NFH levels and/or distribution. NFH is one of four proteins that make up neurofilament, a cytoskeletal protein necessary for structural integrity and axon diameter [40]. While it is known that phospho-NFH and NFL are not elevated in the plasma of SBMA patients [38, 39], this finding does not preclude their potential pathological importance. Genetic ablation
of Nefl and the subsequent alteration of the 4:1:1 neurofilament subunit ratio (NFL:NFM:NFH) has been shown to alter the structural integrity of neurofilaments, resulting in decreased axon caliber and decreased neuronal conduction velocity [12, 28, 76]. It is known that the decreased uNFH observed in spinal motor neurons of the SBMA transgenic mouse model evaluated in this study is partially rescued upon disease amelioration, concomitant with a partial rescue of motor function, suggesting pathological importance [6, 50]. The decrease in uNFH seen in NMJs of the gastrocnemius provides evidence for a deficit at both ends of the motor neuron – in the soma [5] and at the NMJ. In contrast, NMJs of knock-in mouse TA show significantly increased pNFH. However, it should be noted that in both knock-in and transgenic mice, there is a subset of NMJs with higher pNFH intensity at the axon terminal. Previous studies have shown that proteasome dysregulation by genetic ablation of USP14 results in swellings of pNFH at the axon terminal [4]. Therefore, proteasome dysregulation, known to be present in SBMA [50, 59] might play a contributing role in the observed increased pNFH intensity at this subset of NMJs.

The NFH deficit seen in this study could result in decreased motor neuron conduction velocity, and therefore contribute to motor phenotypes. We considered carrying out electrophysiological studies to evaluate if motor neurons showing a decrease in NFH levels and/or distribution exhibited reduced conduction velocity, and to examine whether this correlated with glycolytic-to-oxidative fiber type switching seen in TA and gastrocnemius. However, stimulation and recording of the sciatic nerve would not allow for precise measurement of motor neurons innervating the muscles that have undergone fiber type switching. To provide electrophysiological evidence for motor neurons innervating “switched” myofibers, motor neurons would need to be individually separated and evaluated for firing rate in vivo, which was beyond the scope of this study. Future studies using in vitro models of the neuromuscular junction could yield important information on motor neuron firing rate changes in SBMA models. In addition to its role in regulating axon diameter, NFH also has a role at the pre-synaptic terminal in determining the size of the readily releasable pool of synaptic vesicles and positioning organelles for energy needs [14, 76]. For example, NFH interacts with mitochondria, which are more abundant at the NMJ than at central synapses due to the high energy demands of the NMJ [68]. It is known that mitochondrial functions are altered in SBMA [52, 56]. Further experimentation to evaluate mitochondrial density at the NMJ due to neurofilament loss is warranted, as a decrease in mitochondrial density could contribute to neurotransmission failure in SBMA. Notably, loss of NFH could also be a downstream effect of neuronal dysfunction in the face of the toxic gain-of-function of the polyglutamine-expanded AR. Considering these data and the known roles of NFH in the neuron, the deficit in NFH localization at the presynaptic terminal could result in less readily available synaptic vesicles, fewer mitochondria, and a general lack of structural integrity, altering the functional ability of the nerve terminal. Future studies to elucidate the extent to which neurofilament proteins (NFL, NFM, NFH, and peripherin) are altered in SBMA mouse models in spinal cord motor neurons and sciatic nerve are needed to fully understand the role of neurofilaments in SBMA pathogenesis.

While fragmentation has canonically been used to describe disease pathology at the NMJ [10, 63], we observed significant NMJ fragmentation only in the TA muscle. The modest changes in fragmentation seen in this study, concomitant with significant changes in other measures of NMJ pathology, highlights the importance of including quantitative measurements when evaluating a disease such as SBMA, where neuronal and muscular alterations have a dynamic effect on the NMJ. While fragmentation was only significantly altered in TA, all three muscles presented with significant decreases in post-synaptic area and endplate area. These post-synaptic changes in soleus, TA, and gastrocnemius were accompanied by decreased muscle fiber cross-sectional area in all three muscles. It is known that post-synaptic size positively correlates with muscle fiber cross-sectional area [29, 61]. Therefore, the decrease in post-synaptic size could be secondary to the decrease in myofiber cross-sectional area or due to primary NMJ pathology. The directionality of this pathology is unable to be discerned from these studies. In addition, it is unclear whether the decrease in cross-sectional area is due to muscle atrophy or fiber type switching, as slow-twitch oxidative myofibers are smaller than fast-twitch glycolytic myofibers [3].

All three muscles evaluated showed a shift towards oxidative metabolism as measured by NADH-diaphorase staining, except for transgenic soleus muscle, which showed decreased NADH-diaphorase staining. The oxidative-to-glycolytic shift in transgenic soleus could be a result of altered metabolism, as mice deficient in mitochondrial long-chain fatty acid synthesis show an oxidative-to-glycolytic shift in slow-twitch soleus muscles [49]. The decreased NADH staining could also be due to reduced oxidative capacity, as mitochondrial depolarization and ATP production is decreased in models of SBMA [7, 52, 58]. It is worth noting that we cannot derive information on the efficiency of energy production in these muscles, as NADH-diaphorase staining measures only the presence of the necessary mitochondrial enzyme to deposit the stain, not mitochondrial activity, per se.
Future metabolomic and proteomic studies on the muscles of these models will help to further deconstruct the observed metabolic changes.

It is important to clarify that while muscle fibers show convincing evidence of a glycolytic-to-oxidative shift in metabolic state based on NADH-diaphorase staining, these data do not support changes in myosin heavy chain isotype expression in gastrocnemius or TA that would indicate ‘fiber-type switching’ at a cytoskeletal protein expression level. The distinction between metabolic and cytoskeletal ‘fiber-type’ should be taken into consideration when evaluating neuromuscular disease, as the contractile properties of the myofiber may be discordant with its metabolic state. Previous studies have shown that mice defective in mitochondrial long chain fatty-acid synthesis showed alterations in mitochondrial metabolism that were discordant with myosin heavy chain expression [49]. Coordination of slow-twitch metabolic and cytoskeletal characteristics requires co-activation of PGC1α with Mef2 [35]. Mef2 transcriptional targets were shown to be decreased in knock-in mouse muscles due to sequestration of Mef2 in polyglutamine-expanded AR-containing intranuclear inclusions [47]. The evaluation of PGC1α protein levels in our study was inconclusive (data not shown). Nonetheless, it is likely that Mef2-specific transcriptional dysregulation [47], along with known global transcriptional and translational deficits [33, 62], contribute to the muscular cytoskeletal dysregulation observed in this study. Interestingly, increased vinculin protein expression observed in both mouse models of SBMA provides evidence for selective cytoskeletal changes that correlate with metabolic glycolytic-to-oxidative fiber type switching, as vinculin is known to be more highly expressed in slow-twitch oxidative myofibers [8]. Additionally, increased vinculin could be a sign of neurotransmission failure, as vinculin levels are known to increase upon denervation [57]. Understanding the nature of the distinct alteration in this myofiber cytoskeletal component is the focus of future studies. Of note, vinculin plays an analogous role in cardiac muscle. Vinculin’s role in SBMA cardiac phenotypes should be considered for further research, as SBMA patients have an increased prevalence of Brugada Syndrome, a cardiac syndrome that can lead to ventricular fibrillation and early death [1, 32].

In this study, we observed some differences between the two mouse models of SBMA. To understand the model-specific pathology, we considered that the mouse models used here differ in both age and polyglutamine-expanded AR expression. The transgenic model, which over-expresses polyglutamine-expanded AR primarily in the nervous system, showed no significant NMJ pathology at 6 months of age, despite significant motor deficits [5, 77]. In contrast, the knock-in model, which expresses endogenous polyglutamine-expanded AR, showed significant NMJ pathology in gastrocnemius muscle at 6 months of age. By 1-year of age, transgenic mice showed significant pathology in all three muscles evaluated. One possible explanation for the increased NMJ pathology in the transgenic mice is the higher levels of polyglutamine expanded AR in the spinal cord of the transgenic model [5, 77]. The overexpression of mutant AR in the spinal cord and brainstem could have contributed to broader NMJ pathology, independent of motor unit subtype, since mutant AR is overexpressed in all spinal cord neurons. The hypothesis that the differences between models are due to differences in polyglutamine expanded AR expression is not mutually exclusive of the hypothesis that the differences between models are due to the difference in age. The comparison of SBMA models of different ages is a limitation of this study; however this comparison evaluated NMJ pathology at timepoints known to be devoid of motor neuron loss. It is worth noting that primary spinal cord cultures from both the transgenic and knock-in mouse models exhibit substantial motor neuron cell death in response to hormone treatment [20, 45, 48, 50], indicating intrinsic motor neuron vulnerability in both models. Notably, it is unknown how polyglutamine-AR expression in glial cells of the spinal cord or terminal Schwann cells of the NMJ might affect the specificity of motor unit pathology. Further research into the role of glia in SBMA pathogenesis is needed, especially considering the importance of terminal Schwann cells in NMJ health.

A limitation of this study is the heterogenous nature of the muscles evaluated. While both gastrocnemius and TA represent “fast-twitch muscles”, they both contain a mixture of muscle fiber types that are known to change with age and anatomical location within the muscle [3, 25]. Because whole muscles were dissected and teased into small bundles prior to staining and imaging of en face NMJs, a random sample of NMJs was evaluated from each muscle. This random sample, combined with the heterogenous nature of the muscles evaluated, may have limited the power of this study to detect NMJ pathology in specific motor unit subtypes. However, while these data cannot provide insight on individual motor units, they do provide evidence to support increased vulnerability of muscles containing primarily fast-twitch myofibers in SBMA mouse models.

Our model (Fig. 10) proposes that glycolytic-to-oxidative metabolic fiber-type alterations and decreased myofiber cross-sectional area are correlated with a decrease in NMJ post-synaptic membrane size and other NMJ pathologies, making fast-twitch motor units more vulnerable to SBMA pathogenesis than slow-twitch motor units.
Glycolytic-to-oxidative motor unit changes and myofiber atrophy could be the result of either denervation, neuromuscular transmission dysfunction due to NMJ structural defects, or changes in motor neuron firing rate. Equally likely is that changes in myofiber metabolism and a decrease in fiber size promote changes in motor neuron firing rate and NMJ reorganization. Our quantitative analyses of NMJ pathology were largely in keeping with our hypothesis that NMJ pathology is correlated with muscle type vulnerability seen in SBMA mouse models and SBMA patients. Moreover, our study revealed a novel relationship between neurofilament dysregulation at the NMJ and both pre- and post-synaptic pathology. However, our observations of differences in NMJ pathology between gastrocnemius and TA suggest that motor unit vulnerability may also be impacted by inherent differences in the rate of synapse formation (e.g., fast synapsing vs. delayed synapsing). In addition, the oxidative shift in gastrocnemius and TA muscles, in the absence of myosin heavy chain isoform switching, may also contribute to the NMJ pathologies observed here. A deep understanding of the relationship between NMJ pathology and both neuronal and muscle alterations is likely to provide novel insights into approaches to enhance NMJ neurotransmission and disease progression in SBMA.

**Abbreviations**

α-BTX: Alpha-bungarotoxin; AChR: Acetylcholine receptor; ALS: Amyotrophic lateral sclerosis; AR: Androgen receptor; CSA: Cross-sectional area; DeSyn: Delayed-synapsing; FaSyn: Fast-synapsing; KI: Knock-in; MHC: Myosin heavy chain; MIP: Maximum intensity projection; NADH: Nicotinamide adenine dinucleotide hydrogen; NMJ: Neuromuscular junction; NTg: Non-transgenic; PFA: Paraformaldehyde; pNFH: Phosphorylated neurofilament heavy chain; SBMA: Spinal bulbar muscular atrophy; SMA: Spinal muscular atrophy; TA: Tibialis anterior; Tg: Transgenic; TUJ1: BIII-tubulin; uNFH: Unphosphorylated neurofilament heavy chain; WT: Wildtype.

**Supplementary Information**

The online version contains supplementary material available at [https://doi.org/10.1186/s40478-022-01402-y](https://doi.org/10.1186/s40478-022-01402-y).

**Additional file1**. Supplementary Methods. Supplementary Figs. 1–9. Supplementary Tables 1 and 2.
Acknowledgements

We would like to thank members of the Merry lab for helpful discussions. Data reported in this manuscript utilized the Bioimaging Facility at Sidney Kimmel Cancer Center at Jefferson Health and was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA056036. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Author contributions

DEM and EM conceptualized the research and DEM oversaw the research. EM collected and analyzed all NMJ data, analyzed NADH-diaphorase data, collected and analyzed muscular western blot data, designed the proposed model, and led manuscript writing along with DEM. YL handled mouse colonies and performed NADH staining on all muscles. APL provided knock-in mouse models and was a contributor in writing the manuscript. DEM is the principle investigator on this study and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Institutes of Health Grant Nos. R01NS090335 to DEM and R01NS119873 to APL.

Availability of data and materials

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Jefferson Alumni Hall, Rm. 411E, Philadelphia, PA 19107, USA. 2Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.

Received: 13 May 2022 Accepted: 23 June 2022

Published online: 05 July 2022

References

1. Araki A, Katsuno M, Suzuki K, Banno H, Suga N, Hashizume A et al (2014) Brugada syndrome in spinal and bulbar muscular atrophy. Neurology 82(20):1813–1821

2. Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, Katsuno M et al (2006) Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129(6):1446–1455

3. Augusto V, Padovani C, Eduardo G, Campos R (2004) Skeletal muscle fiber types in CS7B61 mice. J Morphol Sci 218:89–94

4. Chen P-C, Qin L-N, Li X-M, Walters BJ, Wilson JA, Mei L et al (2009) The proteasome-associated deubiquitinating enzyme USP14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions. J Neurosci 29(35):10909–10919

5. Chevalier-Larsen E, O’Brien CJ, Wang H, Jenkins SC, Holder L, Lieberman AP et al (2004) Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24(20):4778–4786

6. Chevalier-Larsen E, Merry DE (2012) Testosterone treatment fails to accelerate disease in a transgenic mouse model of spinal and bulbar muscular atrophy. Dis Model Mech 5(1):141–145

7. Chivet M, Marchioretti C, Pirazzini M, Piot D, Scaramuzzino C, Polanco MJ et al (2020) Polyglutamine-expanded androgen receptor alteration of skeletal muscle homeostasis and myonuclear aggregation are affected by sex, age and muscle metabolism. Cells 9(2):325–325

8. Chopard A, Pons F, Marinir JF (2002) Vinculin and meta-vinculin in fast and slow rat skeletal muscle before and after hindlimb suspension. Pflug Arch Eur J Physiol 445(5):627–633

9. Cortes C, Ling SC, Guo LT, Hung G, Tsunemi T, Ly L et al (2014) Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron 82(2):295–307

10. Delezie J, Weihrauch M, Maier G, Tejero R, Ham DJ, Gill JF et al (2016) BDNF is a mediator of glycolytic fiber-type specification in mouse skeletal muscle. Proc Natl Acad Sci USA 113(21):16111–16120

11. Dukkipati SS, Garrett TL, Elbasioni NY, The spinal vulnerability of motor neurons is decreased in a mouse model of amyotrophic lateral sclerosis. J Physiol 596(9):1723–1745

12. Elder GA, Friedrich VL, Kang C, Bosco F, Gourov A, Tu PH et al (1998) Requirement of heavy neurofilament subunit in the development of axons with large calibers. J Cell Biol 143(1):195–205

13. Fischbeck KH (1997) Kennedy disease. J Inherit Metab Dis 20(2):152–158

14. Gentil BJ, Tibshirani M, Durham HD (2015) Neurofilament dynamics and involvement in neurological disorders. Cell Tissue Res 360:609–620

15. Gerwin L, Haupt C, Wilkinson KA, Kröger S (2019) Acetylcholine receptors in the equatorial region of intrafusal muscle fibres modulate mouse muscle spindle sensitivity. J Physiol 597(7):1993–2006

16. Giorgetti E, Yu Z, Chua JP, Shimamura R, Zhao L, Zhu F et al (2016) Rescue of metabolic alterations in AR113Q skeletal muscle by peripheral androgen receptor gene silencing. Cell Rep 17(1):125–136

17. Harding AE, Thomas PK, Baratier M, Bradbury PG, Morgan-Hughes J, Ponsford JR (1982) X-linked recessive bulbospinal neuropathy: a report of ten cases. J Neurol Neurosurg Psychiatry 45(11):1012–1019

18. Hegedus J, Putman CT, Gordon T (2007) Time course of preferential motor unit loss in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 28(2):154–164

19. Hegedus J, Putman CT, Tyerman N, Gordon T (2008) Preferential motor unit loss in the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Physiol 586(14):3337–3351

20. Heine EM, Berger TR, Pluimen J, Orr CR, Zbroav L, Merry DE (2015) Proteasome-mediated proteolysis of the polyglutamine-expanded androgen receptor is a late event in spinal and bulbar muscular atrophy (SBMA) pathogenesis. J Biol Chem 290(20):21257–21264

21. Jokela M, Huovinen S, Raheem O, Lindfors M, Palmio J, Penttila S et al (2016) Distinct muscle biopsy findings in genetically defined adult-onset motor neuron disorders. PLoS ONE 11(3):1–11

22. Hoffman PN, Cleveland DW (1988) Neurofilament and tubulin expression recapitulates the developmental program during axonal regeneration: Induction of a specific β-tubulin isotype. Proc Natl Acad Sci USA 85(12):4530–4533

23. Jokela M, Huovinen S, Raheem O, Lindfors M, Palmio J, Penttila S et al (2016) Distinct muscle biopsy findings in genetically defined adult-onset motor neuron disorders. PLoS ONE 11(3):1–11

24. Jones RA, Reich CD, Dissanyake KN, Kristmundsdottir F, Findlater GS, Ribchester RR et al (2016) NMJ-morph reveals principal components of synaptic morphology influencing structure-function relationships at the neuromuscular junction. Open Biol 6(2):1–16

25. Kanda K, Hashizume K (1998) Changes in properties of the medial gastrocnemius motor units in aging rats. J Neurophysiol 80(2):737–746

26. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H et al (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuroreport 13(5):843–845

27. Kemp MQ, Poort JL, Baqri RM, Lieberman AP, Breedlove SM, Miller KE et al (2011) Impaired motoneuronal retrograde transport in two models of SBMA implicates two sites of androgen action. Hum Mol Genet 20(22):4475–4490

28. Kriz J, Zuo Q, Julien JP, Padjen A (2000) Electrophysiological properties of axons in mice lacking neurofilament subunit genes: disparity between conduction velocity and axon diameter in absence of NF-H. Brain Res 885(1):32–44
29. Kuno M, Turkanski SA, Weakly JN (1971) Correlation between nerve terminal size and transmitter release at the neuromuscular junction of the frog. J Physiol 213(3):545–556
30. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352(6330):77–79
31. Li L, Xiong W-C, Mei L (2018) Neuromuscular junction formation, aging, and disorders. Annu Rev Physiol 80(1):159–188
32. Li M, Nakagomi Y, Kobayashi Y, Merry D, Tanaka F, Doyu M et al (1998) Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol 153(3):695–701
33. Lieberman AP, Harmison G, Strand AD, Olson JM, Fischbeck KH (2002) Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet 11(17):1967–1976
34. Lieberman AP, Yu Z, Murray S, Peralta L, Wool G, Su et al (2014) Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep 7(3):774–784
35. Ling KKY, Gibbs RM, Feng Z, Ko C-P (2012) Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Hum Mol Genet 21(11):185–195
36. Liu Y, Padget A, Liu J, Nakagomi M, Li H, Shaved A, Teichert RW et al (2022) Essential roles of the acetylcholine receptor γ-subunit in neuromuscular synaptic patterning. Development 135(1):1957–1967
37. Lombardi V, Bombaci A, Zampedri L, Lu C-H, Malik B, Zetterberg H et al (2020) Plasma pNFH levels differentiate SBMA from ALS. J Neurol Neurosurg Psychiatry 91:215–217
38. Lombardi V, Querin G, Ziff OJ, Zampedri L, Martinelli I, Heller C et al (2019) Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology 92(11):E1205–E1211
39. Lombardi V, Bombaci A, Zampedri L, Lu C-H, Malik B, Zetterberg H et al (2020) Plasma pNFH levels differentiate SBMA from ALS. J Neurosurg Psychiatry 91:215–217
40. Marszalek JR, Williamson TL, Lee MK, Xu Z, Hoffman PN, Becher MW et al (1996) Neurofilament subunit NF-H modulates axonal diameter by controlling microtubule polymerization. J Cell Biol 135(4):1157–1167
41. Martinez-Silva de Lourdes M, Imhoff-Manuel R, Sharma A, Heckman CJ, Shneider NA, Roselli F et al (2018) Hypoexcitability precedes denervation in the large fast-contracting motor units in two unrelated mouse models of ALS. J Neurophysiol 120(1):99–112
42. Martin M, Li K, Wright MC, Lepore AC (2015) Functional and morphological assessment of diaphragm innervation by pherine motor neurons. J Vis Exp 99:e52605
43. Martínez-Silva de Lourdes M, Imhoff-Manuel R, Sharma A, Heckman CJ, Shneider NA, Roselli F et al (2018) Hypoexcitability precedes denervation in the large fast-contracting motor units in two unrelated mouse models of ALS. J Neurophysiol 120(1):99–112
44. Mazza AM, Jarvis S, Lee WC, Cunningham TJ, Schiavo G, Secrèt M et al (2021) NMJ-analyser identifies subtle early changes in mouse models of neuromuscular disease. Sci Rep 11(1):12251
45. Mishina M, Takai I, Imoto K, Noda M, Takahashi T, Numata S et al (1986) Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature 321(6068):406–411
46. Mojtihovic-Petrovic J, Nedelsky N, Bocchio M, Mano I, Georgiadis SN, Zhou W et al (2009) Foxo3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J Neurosci 29(25):8236–8247
47. Montie HL, Cho MS, Holder L, Liu Y, Tsvetkov AS, Finkbeiner S et al (2009) Cytoplasmic retention of polyglutamylation-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 18(11):1937–1950
48. Nath SR, Lieberman ML, Yu Z, Marchioretto C, Jones ST, Danby ECE et al (2020) Me2z impairment underlies skeletal muscle atrophy in polyglutamine disease. Acta Neuropathol 140(1):63–80
49. Orr CR, Montie HL, Liu Y, Bolzoni E, Jenkins SC, Wilson EM et al (2010) An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem 285(46):35567–35577
50. Pereyra AS, Lin CT, Sanchez DM, Laskin J, Spangenberg EE, Neufeld PF et al (2022) Skeletal muscle undergoes fiber type metabolic switch without myosin heavy chain switch in response to defective fatty acid oxidation. Mol Metab 59:1–16
51. Poort JE, Rheeuben MB, Breedlove SM, Jordan CL (2016) Neuromuscular junctions are pathological but not denervated in two mouse models of spinal bulbar muscular atrophy. Hum Mol Genet 25(17):3768–3783
52. Pourshafie N, Masati E, Bunker E, Nickalls AR, Thepmankorn P, Johnson K et al (2020) Linking epigenetic dysregulation, mitochondrial impairment, and metabolic dysfunction in SBMA motor neurons. JCI Insight 5(13):136539
53. Pun S, Sigrist M, Santos AF, Ruegg MA, Sanes JR, Jessell TM et al (2002) An intrinsic distinction in neuromuscular junction assembly and maintenance in different skeletal muscles. Neuron 34(3):357–370
54. Pun S, Santos AF, Saxena S, Xu L, Caroni P (2006) Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 9(3):408–419
55. Ramzan F, McPhail M, Rao P, Mo K, Halleviski K, Swift-Gallant A et al (2015) Distinct etiological roles for myocytes and motor neurons in a mouse model of Kennedy’s disease/spinobulbar muscular atrophy. J Neurosci 35(16):6444–6451
56. Ranganathan S, Harmison GG, Pennuto M, Burnett BG, Fischbeck KH (2009) Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet 18(1):27–42
57. Rezvani M, Ornatsky OI, Connor MK, Eisenberg HA, Hood DA (1996) Dystrophin, vinculin, and actin in skeletal muscle subject to chronic use and disuse. Med Sci Sports Exerc 28(1):79–84
58. Roschi A, Milletto C, Parodi S, Arminotti A, Borgia D, Pellegrini M et al (2016) Glycotoxic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet. Acta Neuropathol 132:127–144
59. Rusmini P, Crippa V, Cristofani R, Rinaldi C, Cicardi ME, Galbiati M et al (2015) The role of the protein quality control system in SBMA. J Mol Neurosci 58(3):348–364
60. Sahaishi K, Katsuno M, Hung G, Adachi H, Kondo N, Nakatsuji H et al (2015) Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 24(21):5985–5994
61. Schiaffino S, Reggiani C (2011) Fiber types in mammalian skeletal muscles. Physiol Rev 91(4):1447–1531
62. Shelia M, Narayanan G, Ma S, Tam WL, Choi J, Stanton LW (2019) Phenotypic and molecular features underlying neurodegeneration of motor neurons derived from spinal and bulbar muscular atrophy patients. Neurobiol Dis 124:1–13
63. Slater CR (2019) Fragmentation of NMJs: a sign of degeneration or regeneration? A long journey with many junctions. Neuroscience 439:28–40
64. Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A (1989) X-linked recessive bulbospinal neuronopathy: a clinicopathological study. Brain 112(1):209–232
65. Soraru G, D’Ascenzo C, Polo A, Palmieri A, Baggio L, Vergani L et al (2020) Cellular/molecular mechanisms of mitochondria-neurofilament interactions. J Neurosci 58(3):348–364
66. Stifani N (2014) Motor neurons and the generation of spinal motor neuron diversity. Front Cell Neurosci 8:293–293
67. Suzuki K, Katsuno M, Banno H, Takeuchi Y, Kawashima M, Sugna et al (2010) The profile of motor unit number estimation (MUNE) in spinal and bulbar muscular atrophy. J Neurol Neurosurg Psychiatry 81:567–571
68. Wagner OI, Lifshitz J, Janney PA, Linden M, McIntosh TK, Letterer JF (2003) Cellular/molecular mechanisms of mitochondria-neurofilament interactions. J Neurosci 23(27):9046–9058
69. Wang S, Seaberg B, Penaz-Colasante X, Rimer M (2016) Defective acetylcholine receptor subunit switch precedes atrophy of slow-twitch skeletal muscle fibers lacking ERK1/2 kinases in soleus muscle. Sci Rep 6(38745):1–14
70. Xu K, Jha S, Hoch W, Dryer SE (2006) Delayed synapsing muscles are delayed in the development of synaptic transmission without myosin heavy chain switch in response to defective fatty acid oxidation. Mol Metab 59:1–16
71. Xu Y, Halleviski K, Henley C, Atchison WD, Katsuno M, Adachi H et al (2016) Defects in neuromuscular transmission may underlie motor dysfunction in spinal and bulbar muscular atrophy. J Neurosci 36(18):5094–5106
72. Xu Y, Halievski K, Katsum M, Adachi H, Sobue G, Breedlove SM et al (2018) Pre-clinical symptoms of SBMA may not be androgen-dependent: Implications from two SBMA mouse models. Hum Mol Genet 27(14):2425–2442
73. Yamada S, Hashizume A, Hikijata Y, Inagaki T, Suzuki K, Kondo N et al (2016) Decreased peak expiratory flow associated with muscle fiber-type switching in spinal and bulbar muscular atrophy. PLoS ONE 11(12):e0168846–e0168846
74. Yu Z, Dadgar N, Albertelli M, Grus K, Jordan C, Robins DM et al (2006) Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Investig 116(10):2663–2672
75. Yu Z, Dadgar N, Albertelli M, Scheller A, Albin RL, Robins DM et al (2006) Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. Am J Pathol 168(1):195–204
76. Yuan A, Rao MV, Nixon RA (2017) Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 9(4):1–24
77. Zboray L, Pluciennik A, Curtis D, Liu Y, Berman-Booty Lisa DD, Orr C et al (2015) Preventing the androgen receptor N/C interaction delays disease onset in a mouse model of SBMA. Cell Rep 13(10):2312–2323
78. Zhao Y, Szaro BG (1995) The optic tract and tectal ablation influence the composition of neurofilaments in regenerating optic axons of Xenopus laevis. J Neurosci 15(6):4629–4640

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.